



(국문/영문)이름: 김이랑/Yirang Kim

(국문/영문)직위: 창업자 및 대표이사/Founder & Co-CEO

(국문/영문)소속: 온코크로스/ONCOCROSS

(국문/영문)기타소속: AI 신약개발협의회 회장/Chairman of Council for AI Drug Discovery & Development

국문 강연제목: AI 로 찾아가는 약물의 새로운 적응증

**영문 강연제목: AI-Powered Drug Development Platforms:
Discovering New Therapeutic Indications**

Abstract(영문):

A recent case in which a diabetes drug achieved indication expansion into obesity and became a blockbuster highlights the growing importance of this strategy. Conventional approaches, based on literature or known mechanisms of action, remain limited in uncovering novel opportunities. Oncocross has developed RAPTOR AI, an AI-driven platform that analyzes transcriptome-based gene expression changes to predict drug-disease associations independent of known mechanisms. This enables the discovery of entirely new therapeutic indications, including optimal or additional indications for drugs in development, alternative uses for failed assets, evergreening opportunities for near-patent-expiration drugs, and candidates for rare or intractable diseases. By reducing cost, shortening development timelines, and minimizing failure risk, RAPTOR AI supports more efficient drug development and is already being applied in collaborations with domestic and global pharmaceutical and biotech partners.

Brief Biosketch (간단한 이력, 연구/대외활동 소개,국문/영문)

서울아산병원에서 트레이닝 받은 Medical Oncologist 이자, 카이스트에서 박사학위를 취득한 의사과학자로, 온코크로스를 통해 암 및 희귀질환 진단 및 치료제 개발에 힘쓰고 있으며, AI 신약개발협의회 회장으로 AI 신약개발 저변확대에도 노력하고 있다.

He is a board-certified Medical Oncologist who received his clinical training at Asan Medical Center and earned his Ph.D. from KAIST as a physician-scientist. Through Oncocross, he is committed to advancing the development of diagnostics and therapeutics for cancer and rare diseases. In addition, as Chairman of Council for AI Drug Discovery & Development, he is actively working to promote and expand the role of AI in drug development.